The largest community of pharma leaders

STRAP Technologies Announces Groundbreaking Device to Aid the Visually Impaired

AUSTIN, Texas–()–STRAP Technologies announced today, on White Cane Safety Day in the United States, the creation of a hands-free device designed to be worn by the visually impaired to allow for more independence and mobility.

STRAP is a wearable, hands-free device with an innovative array of sensors that work by sending real-time information that detect obstacles at the head, chest and below — including oncoming bumps, holes, overhanging objects and steps. The haptic language notifications also make STRAP an intuitive device to use and easy to learn in less than two minutes. STRAP is designed for all ages and abilities, and offers obstacle detection, stair detection, advanced haptic feedback, straight line navigation and orientation. It can also distinguish between physical objects and people. The device once charged can last up to 72 hours and is easy to recharge with a magnetic charger provided.

The device was first developed in Mexico by STRAP Technologies CEO and Founder, Diego Roel, who comes from an extensive background in robotics, new product ideation, R&D and IP strategy. “STRAP is the first assistive technology on the market that replaces the white cane that’s been in use for over 100 years,” Roel said.

“We’ve spent three years on the research and development of STRAP to invent a product that is truly innovative. We are really passionate about changing the way the blind and visually impaired explore the world; our core mission is that we believe autonomy and independence is a human right; not a luxury.”

STRAP Technologies is headquartered in Austin, Texas, with a Research and Development lab in Guadalajara, Mexico. The device is now available for preorder at an introductory price of $500 with a $50 deposit.

For more information, visit


Recent Articles

ONK Therapeutics Closes New Financing and Appoints Chris Nowers as CEO

GALWAY, Ireland--(BUSINESS WIRE)--ONK Therapeutics Ltd, an innovative natural killer (NK) cell therapy company, today announced that it has raised US$8M in a financing from...

Transgene: Acceptance of Late Breaking Abstract at Upcoming SITC 2020 Conference, on The Detailed Results From Clinical Study of TG4001 in Combination With Avelumab...

STRASBOURG, France--(BUSINESS WIRE)--Regulatory News: Transgene (Paris:TNG) (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapeutics against cancer, announced that detailed results of...

Akron Biotech Signs Agreement With Synairgen plc to Supply Interferon-beta for COVID-19 Treatment

BOCA RATON, Fla.--(BUSINESS WIRE)--Akron Biotechnology today announced it has signed an agreement with Synairgen plc (LSE: SNG) for the provision of SNG001, Synairgen’s wholly-owned...

Ultimovacs Announces Updated Positive Results from Phase I Trial Evaluating Universal Cancer Vaccine, UV1, in Non-Small Cell Lung Cancer

OSLO, Norway--(BUSINESS WIRE)--Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced five-year overall survival data from the Phase I trial evaluating UV1 as maintenance therapy in...

Genesis Therapeutics Enters AI-driven, Multi-Target Drug Discovery Partnership with Genentech

BURLINGAME, Calif.--(BUSINESS WIRE)--Genesis Therapeutics, a privately-held company inventing and deploying state-of-the-art artificial intelligence (AI) techniques to augment drug discovery and development, today announced that...